TMCnet News
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingBOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics, CUE-101 in recurrent/metastatic head and neck cancer and CUE-102 in Wilms’ Tumor 1 positive recurrent/metastatic cancers. The Company will host a Business Update call and webcast in June 2024 that will include a discussion on the clinical progress and associated data presented at ASCO on June 1 and June 4. Call details will be issued prior to the event. Oral Abstract and Poster Details Abstract Number: 6004 Abstract Number: 3553 Session Type and Title: Poster Session; Gastrointestinal Cancer, Colorectal and Anal Session Date and Time: June 1, 2024, 1:30 PM-4:30 PM CDT The oral abstract and poster presentations will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following ASCO. About Cue Biopharma Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit www.cuebiopharma.com and follow us on Twitter and LinkedIn. Investor Contact Media Contact |